Role of HER-2/neu in gynecologic malignancies

Contemporary Ob-Gyn

Volumn 41, Issue 7, 1996, Pages 49-75

  Cirisano, Frank D ^a   Karlan, Beth Y ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0342910744     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226
2. Coussens LT, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132
3. King CR, Kraus MH, Aaronson SA, et al: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974
4. Scott GK, Robles R, Park JW, et al: A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 1993;13:2247
5. Alper O, Yamaguchi K, Hitomi J, et al: The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-Br-3. Cell Growth Differ 1990;1:591
6. Samba K, Kamata N, Toyoshima K, et al: A v-erbB related proto-oncogene, c-erbB-2 is distinct from c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Am Assoc Cancer Res 1985;82:6497
7. Bargmann CI, Hung MC, Weinbeg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;290:261
8. Stern DF, Kamps MP: EGF-emulated tyrosine phosphorylation of p185 neu: A potential model for receptor interactions. EMBO J 1988;7:995
9. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707
10. Lemoine NR, Staddon S, Dickson C, et al: Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene. Oncogene 1990;5:237
11. Yarden Y, Weinberg RA: Experimental approaches to hypothetical hormones: Detection of a candidate ligand of the neu prolo-oncogene. Proc Natl Acad Sci 1989;86:3179
12. Lupu R, Colomer R, Zugmaier G, et al: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185 erbB2. Science 1990;249:1552
13. Yarden Y, Peles E: Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry 1991;30:3543
14. DiFiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in N1H/3T3 cells. Science 1987;237:178
15. Akiyama T, Saito T, Ogawar H, et al: Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-erbB-2 gene product in MKN-7 human adenocarcinoma cells. Mol Cell Biol 1988;8:1019
16. King CR, Borrello I, Bellot F, et al: EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in mammary tumor cell line SK-BR-3. EMBO J 1988;7:1647
17. Connelly PA, Stem DF: The epidermal growth factor receptor and the product of the neu proto-oncogene are members of a receptor tyrosine phosphorylation cascade. Proc Natl Acad Sci 1990;87:6054
18. Pruss RM, Herschman HR: Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. Proc Natl Acad Sci 1977;74:3918
19. Kokai Y, Myers JN, Wada T, et al: Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989;58:287
20. Chazin VR, Kaleko M, Miller AD, et al: Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859
21. Weiner DB, Kokai Y, Wada T, et al: Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene 1989;4:1175
22. Akiyama T, Matsuda S, Namba Y, et al: The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl terminal domain. Mol Cell Biol 1991;11:833
23. Shin C, Padhy LC, Murray M, et al: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981;290:261
24. Un YJ, Clinton GM: A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991;6:639
25. Zabrecky JR, Lam T, McKenzie SJ, et al: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-Br-3. J Biol Chem 1991;266:1716
26. Basu A, Raghunath RM, Bishayee S, et al: Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: Role for interreceptor interaction in kinase regulation. Mol Cell Biol 1989;9:9671
27. Flickinger TW, Mainte NJ, Kung HJ, et al: An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol 1992;12:883
28. Bacus SS, Huberman E, Chin D, et al: A ligand for the erbB-2 oncogenic product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differ 1992;3:401
29. Bacus SS, Stancovski I, Huberman D, et al: Tumor inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells. Cancer Res 1992;52:2580
30. Holmes WE, Sliwkowski MX, Akita RW, et al: Identification of Heregulin, a specific activator of p185 erbB-2. Science 1992;256:1205
31. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu Oncogene. Science 1987;235:177
32. Seshadrj R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936
33. Wada T, Qian XL, Greene MI: Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function. Cell 1990;61:1337
34. Yarden Y: Agonistic antibodies stimulate the kinase encoded by the neu proto-oncogene in living cells but the oncogenic mutant is constitutively active. Proc Natl Acad Sci 1990;87:2569
35. Samanta A, LeVea CM, Dougall WC, et al: Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci 1994;91:1711
36. Kacinski BM, Carter D, Kohorn EI, et al: Oncogene expression in vivo by ovarian adenocarcinomas and mixed-mulierian tumors. Yale J Biol Med 1989;62:379
37. Kacinski BM, Mayer AR, King BI, et al: Neu protein overexpression in benign, borderline and malignant ovarian neoplasms. Gynecol Oncol 1992;44:245
38. Berchuck A, Rodriguez G, Kinney RB, et al: Overexpession of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15
39. Hetzel DJ, Wilson TO, Keeney GL, et al: HER-2/neu expression: A major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179
40. Shepard HM, Lewis GD, Sarup JC, et al: Monoclonal antibody therapy of human cancer: Taking HER-2 protooncogene to the clinic. J Clin Immun 1991;11:117
41. Schecther AL, Stem OF, Vaidyanathan L, et al: The neu oncogene: An erb-B-related gene encoding a 185,000-M tumour antigen. Nature 1984;312:513
42. Berchuck A, Kamal A, Whitaker R, et al: Over-expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087
43. McKenzie SJ, DeSombre KA, Bast BS, et al: Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185 neu in human ovarian cancer. Cancer 1993;71:3942
44. Karlan BY, Jones J. Slamon DJ, et al: Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol 1994;53:70
45. Cane P, Azen C, Lopez E, et al: Tumor marker trends in asymptomatic women at risk for ovarian cancer: Relevance for ovarian cancer screening. Am J Obstet Gynecol. in press
46. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759
47. Bodmer W, Bishop T, Karran P: Genetic steps in colorectal cancer. Nature 1994;6:217
48. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. NEJM 1988;319:525
49. Bishop JM: Molecular themes in oncogenesis. Cell 1991;64:235
50. Pisani AL, Barbuto DA, Chen D, et al: HER-2/neu, P53 and DNA analyses as prognosticates for survival in endometrial carcinoma. Obstet Gynecol. in press
51. Read LD, Keith D, Slamon Katzenellenbogen BS: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990;50:3947
52. Pietras RJ, Fendly BM, Chazin VR, et al: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer. Oncogens 1994;9:1829
53. Zaret KS, Yamamoto KR: Reversible and persistent changes in chromatin structure accompany activation of a glucocorticoid-dependent enhancer element. Cell 1984;38:29
54. Brock ML, Shairo DJ: Estrogen stabilizes vitellogenin mRNA against cytoplasmic degradation. Cell 1983;34:207